MD

philadelimeats

Gonna sound crazy but one of my best friends' kid is on their meds for MD and it has benefited him greatly. Part of the reason I bought shares.

Adventurous_Floor883

1. a [willingness](https://www.google.com/search?sca_esv=d8b04fc949d05faa&rlz=1C5CHFA_enUS901US904&sxsrf=AE3TifP_xzjRgMgAgZZ3K76T_jQ9ue3CsA:1755039033769&q=willingness&si=AMgyJEuOnAWW0Co4MNdoFOPUEMGALeDrgUHzxtSVX8E2tfiUdmecFPGivXN-1MCc8smRIBbZAdfHM9CQ8QTDRbplqhebIHOgImfnb6KfOxlQ2ze5mXYKyyo%3D&expnd=1&sa=X&ved=2ahUKEwiL2bLxrYaPAxUknWoFHan_MQ4QyecJegQIPxAR) to take bold risks."her audacity came in handy during our most recent emergency"Similar:boldnessdaringfearlessnessintrepiditybraverycouragecourageousnessvalorvalorousnessheroismpluckrecklessnessadventurousnessenterprisedynamismspiritmettleconfidencegutsgutsinessspunkgritbottleballsinessmoxiecojonessandventurousnesstemerariousnessView 1 vulgar slang wordOpposite:timidity 2. 2.rude or [disrespectful](https://www.google.com/search?sca_esv=d8b04fc949d05faa&rlz=1C5CHFA_enUS901US904&sxsrf=AE3TifP_xzjRgMgAgZZ3K76T_jQ9ue3CsA:1755039033769&q=disrespectful&si=AMgyJEubGP9LOKLiAkEY4meu0TgUBOG7czhD3jvABdsDVuFmZaHlL18zR-Kl47-Y0rLrUIMEUlPLBDsyGxdw1mNoaZktc0JCBeqjYc2Z7AXGOm_MD3H1GIM%3D&expnd=1&sa=X&ved=2ahUKEwiL2bLxrYaPAxUknWoFHan_MQ4QyecJegQIPxBR) behavior; impudence. So are you using this as 1 or 2? Just curious. Everbody please stop using that word before it end up like...This

AllPeopleAreStupid

No They pulled out about 2 years ago. I was working at a Dispensary when it happened. Funny because I went to a networking event for them not long before it occurred. It wasn't worth it financially at the time to stay in MD. I think they were paying another company for the pleasure to use their license to operate.

Abject-Advantage528

Analyst 2 year program Goldman -> 2 years hedge fund + postbacc premed -> pivot to MD -> residency in psychiatry finished at 35.

DumbComment101

Exactly, it doesn’t matter what they do. Unless they do something illegal they aren’t going to have issues gaining employment as an MD.

SunDriver408

People get all caught up in investments, it’s important BUT income and raising your floor is the guaranteed path to FatFIRE.   You have the income. You have an excellent opportunity to raise your floor.  5.4% is an excellent fixed income return. As a MD, if independent, maybe you also have an opportunity to own your office building?  

Busy-Association1036

MD

AskGrok

Ah, fellow ape, nothing says "market crash" like seeing red in your piss instead of just your portfolio. Blood in urine (hematuria) can stem from benign stuff like a UTI, kidney stones, or even vigorous exercise, but it could also signal serious issues like infections, bladder problems, or—brace yourself—cancer or kidney disease, per sources like Mayo Clinic and Cleveland Clinic. Recent buzz from MD Anderson notes it's a red flag worth checking ASAP. Don't YOLO this; see a doc immediately for tests. If it's from that all-nighter trading meme stocks, congrats, you've leveled up to physical losses. Stay hydrated, not retarded. Sources: - https://www.mayoclinic.org/diseases-conditions/blood-in-urine/symptoms-causes/syc-20353432 - https://my.clevelandclinic.org/health/diseases/15234-hematuria - https://www.kidneyfund.org/all-about-kidneys/other-kidney-problems/blood-urine-hematuria

jiggolo420

The higher ÀMD goes the more attractive i find Lisa Su 🥵

Effective_Hat_488

This is wrong - to preface I’m an MD that works in biotech venture. The jury is still out on just how efficacious elevidys is, but the two year data was stat sig on all 3 endpoints of NSAA, time to get up and another timed test. 5 year data in 4 patients continues to delay progression meaningfully. Yeah these kids will still have to be in a wheelchair eventually, but limiting progression during their entire lives which can be up to 30 years plus is huge. Peter marks got a lot of flack from folks in biotech when he approved elevidys because it failed the primary endpoint at 1 year but every clinician knows that strong outcomes on good secondary endpoints can outperform it. And from an ecosystem standpoint, you need to have a company generate some money in this area to encourage others to enter the area too. So marks knew this. I was skeptical on first approval as well but the two year and 5 year data has convinced me that it’s definitely doing something. If your son had DMD you’d probably want to try this or watch him waste away only on steroids.

Classic-Finish-7433

Mezze bowl market is over saturated. So many better local shops like here in MD like Moby Dick and Naz’s. Cava is pretty mid

Worried-Angle6504

Confirmed Dates & Events August  7, 2025 — Annual (Virtual) Meeting of Stockholders at 9:00 AM Eastern Time. August 14–16, 2025 — SNO/ASCO CNS Metastases Conference in Baltimore, MD (Baltimore Waterfront Marriott). Within the conference: August 14, 2025, 6:15 – 7:15 PM ET — LM Educational Symposium hosted by Plus Therapeutics, titled “Reimagining Your Approach to Leptomeningeal Metastases.” August 14, 2025, 7:15 – 9:00 PM ET — CNSide Diagnostics Presentation (FORESEE study: CSF Tumor Cell Detection) by Dr. Priya Kumthekar in Grand Ballroom VI. August 15, 2025, 3:25 – 4:50 PM ET — ReSPECT‑LM Trial Data Presentation (REYOBIQ safety and efficacy results) by Dr. Andrew Brenner in Grand Ballroom As you can see there's lots of catalysts coming yet I think even if a RS was to happen it doesn't matter at this point, you don't book out an entire hall for a conference to give BAD news!

Worried-Angle6504

Confirmed Dates & Events August  7, 2025 — Annual (Virtual) Meeting of Stockholders at 9:00 AM Eastern Time. August 14–16, 2025 — SNO/ASCO CNS Metastases Conference in Baltimore, MD (Baltimore Waterfront Marriott). Within the conference: August 14, 2025, 6:15 – 7:15 PM ET — LM Educational Symposium hosted by Plus Therapeutics, titled “Reimagining Your Approach to Leptomeningeal Metastases.” August 14, 2025, 7:15 – 9:00 PM ET — CNSide Diagnostics Presentation (FORESEE study: CSF Tumor Cell Detection) by Dr. Priya Kumthekar in Grand Ballroom VI. August 15, 2025, 3:25 – 4:50 PM ET — ReSPECT‑LM Trial Data Presentation (REYOBIQ safety and efficacy results) by Dr. Andrew Brenner in Grand Ballroom

GetCashQuitJob

No, but it would be good for me in MD when all the richies from NW move out.

Academic_Wafer5293

There's many metrics and they measure different things. PE ratio is a comparison tool but only effective for companies in the same industry. Even then there's so many differences between the companies that PE becomes just one data point in a sea of data points. For growth companies - I like to look at P/S and revenue growth. The E in PE can change drastically depending on how the company chooses to use its free cash flow. For example, Amazon spent decades with almost no earnings so it can (1) build out its logistic empire and (2) pay less taxes. The company kept growing but you'd never see that if you looked just at PE. PE also doesn't tell you squat about what the company's next growth driver may be. Using Amazon again, PE could never foresee AWS. The cash flow statement and analyzing their R&D could give you insights. That requires reading their 10-K and 10-Qs, focusing on the MD&A, not just looking at a PE screener.

ManyCommunications

Insane how an OF chick makes more money than my MD that “manages” $15B

Traditional_Hair_453

Assholes of ass MD

GenesGeniesJeans

Ayyyyyyyyyyyy MD, bruh

AbbreviationsActual9

not why drug prices are so high here and he knows this. he tried to pass a law at the end of his 1st term setting prices to other developed nation prices but was struck down in the courts. or this dude might just be losing it and the tariffs are his brain glitching out. I'd personally like to see his 1st approach re addressed but with more of a push back against the pharma lobby. while true that US profits are a major source of research funding, the industry is not one of small margins. in fact, business is a booming. one might even claim the burden is somewhat overstated. per pro publica: "Dr. Hagop Kantarjian, a leukemia specialist at MD Anderson Cancer Center who studies drug pricing, said that pharmaceutical companies often overstate the cost of developing drugs and that many drug discoveries originate in hospital and academic labs funded through government grants. Funding from the U.S. National Institutes of Health contributed to all but two of the 356 drugs approved by the Food and Drug Administration from 2010 to 2019, according to a Bentley University study. Companies also don’t spend all their profits on innovation: The 14 largest drug companies in the world spent more on stock buybacks and dividend payments to investors than on research and development, according to a 2021 analysis by the U.S. House Oversight Committee. "

LevelUp84

They are like a data consulting organization. Their MD&A in their 10Q should have a batter explanation.

lookskAIwatcher

Not a MD here, but a lot of us who have seen dementia in family members can see what's happening right in front of our eyes. Corporate news media doesn't dare go that far, and here we are.

luvnlife7

Were those deaths the direct result of Elevidys? I understood two weren't related to Elevidys, as one didn't even take Elevidys. I also understand there isn't a cure for MD. The life expectancy for children afflicted with Duchenne Muscular Dystrophy (DMD) is 20-30 years old. Elevansys delays the progression for the kiddos afflicted.

Mysterious_Hat_1890

St Michaels MD is usually packed with boats and people ... weather is as good as it gets . Here this weekend on the boat ... Recession is here puts Monday SPY 595

Zestyclose-Storm-270

Ok so the time to get in is ASAP. This is a LIVE company. Their CNSide platform rolls out commercially within the next 14 days... The perfect time to get would have been on Thursday. We are already up 20% in one day. As for if it is a short term or long term? Let's talk about what the company is doing. Their CNSide platform is rolling out ANY day now. This is going to be starting in only Texas but has the backing of national cancer institute, several renown doctors,physicians, scientists.. And is being rolled out to several hospitals and institutions IMMEDIATELY. Then over the next 13 months they will slowly distribute nationally. This ALONE is an amazing driving factor/catalyst They are having overwhelming success in their clinical trials with their Lead drug REYOBIQ. It is designed to deliver a high dose of radiation directly to tumors in the brain and central nervous system while minimizing harm to surrounding healthy tissues. Plus Therapeutics also has another product in preclinical development called 188RNL-BAM,. This therapy aims to treat solid organ cancers, including primary and secondary liver cancers. They will be presenting at the SNO/ASCO CNS Metastases Conference in Baltimore, MD from August 14-16. They will be showcasing two presentations related to their CNSide platform. One presentation will focus on the ReSPECT-LM clinical trial results, and the other will be an educational symposium.

Fragrant-Calendar-77

I've been following CGTX for almost a year, and the trial results were impressive, as you wrote, reaching 95% efficacy in reducing the main symptoms. Of course, every biotech company is risky, but because CGTX is following the steps and was successful in the FDA Phase 2 meeting, the next steps are very close in the future of a drug. At this FDA Phase 2 meeting, safety and tolerability were discussed, and it was mutually agreed upon. This program, funded by an anonymous donation, positions Zervimesine as a treatment that patients and physicians are already demanding—a strong market signal. The August FDA minutes represent the first major catalyst. A positive result would validate the Phase 3 plans and would likely boost shares, especially if coupled with a BTD grant. Even a partial victory—such as minor design tweaks rather than a complete reformulation—can be optimistic. *In vitro* studies were conducted using neurons derived from a human cell line. Neurons cultured in this way possess many of the functions of cells in the brain. They form long branches that make connections with neighboring cells, move cargo through cells, and recycle cell waste. They may also be damaged by the same toxic elements that drive neurodegenerative disease, such as oxidative stress, which contributes to disease progression. In this way, these cell cultures are useful models of disease states. Zervimesine was shown to arrest further cognitive deterioration in people with mild or moderate Alzheimer’s disease by 129% and 91%, respectively. Anthony Caggiano, MD, PhD, Cognition’s CMO and head of R&D, explained, “This was an important finding as we now know we can identify patients who are more likely to benefit from zervimesine treatment through a simple blood test for p-tau217.” And if price projections are worth anything, analysts are predicting a future share price between $4.00 and the most optimistic predicted a price of $20.00 but according the calculations, it could actually reach 50000% in the short and medium term easily, as the pharmaceutical sector is highly profitable (see the value that Ozempic brought to Novo Nordisk). In other words, CGTX has enormous potential ahead of it because it is developing a single-dose, oral drug for Alzheimer's and Lewy Body Dementia (a market where there is NO drug)... So your analysis and comment on this Reddit post makes perfect sense.. Don't sell the shares just because they fell, the market goes up and down every day, but the fundamentals of CT1812 are very solid.. It's only a matter of time!

BeerNirvana

Here's chat's take on your take: ✅ Mostly True or Reasonably Grounded 1. PSTV is around $0.50 ✔️ True — The stock is trading in the $0.45–$0.55 range as of late July 2025. 2. FDA-cleared trials are ongoing ✔️ True — The FDA recently cleared an IND for REYOBIQ™ (rhenium nanoliposome therapy) for pediatric brain tumors, and CNSide is being clinically evaluated as a liquid biopsy test. 3. Government support ($17.6M in grants) ✔️ Mostly True — PSTV has received non-dilutive DoD and NIH grant funding, including: $3M+ in recent grants (DoD for REYOBIQ), Previous NIH/NCI awards over $14M (combined over time) Exact total ≈ $17M+, depending on how you count. 4. CNSide is being rolled out in hospitals (e.g. MD Anderson) ✔️ Supported — CNSide has been used in clinical trials involving sites such as MD Anderson and City of Hope. It is not FDA-approved yet, but it's in active trial use. ⚠️ Exaggerated or Speculative Claims 5. “1500% upside” / “Analyst targets $10–$20” ❌ Exaggerated No reputable analyst coverage from firms like Piper, JPM, or B. Riley is currently published on PSTV. The $10–$20 targets appear to be community hype projections, not institutional estimates. A 1500% gain from $0.50 would mean $7.50+, which is not supported by any official forecast. 6. “LIVE product” / “Not hype” 🟡 Partially True CNSide and REYOBIQ are both in clinical use, but neither is FDA-approved or commercially launched yet. These are investigational medical products — not revenue-generating commercial therapies. 7. “No dilution” ❌ Misleading PSTV has a history of raising capital through ATM (at-the-market) equity offerings and private placements. In early 2025, they restructured ~$15M in financing. While grants reduce dilution pressure, the company has and may again raise funds through equity when needed. ❗️ Overall Rating: 3.5 out of 5 (Moderately Truthful) Section Rating Notes Price & trial facts ✅ True Based on real SEC and FDA records Government funding ✅ Mostly True Supported by press releases and grants history Commercial rollout 🟡 Partial Product is not yet FDA-approved or for sale Price targets ❌ Exaggerated No official targets confirm 1000%+ upside Dilution claim ❌ Misleading Company has diluted in past ✅ Final Verdict: The review contains some accurate insights, especially around PSTV’s clinical-stage pipeline, grant funding, and activity in brain cancer. But the price targets and urgency ("this will pop") are speculative hype, not grounded in institutional research or financials. If you’re trading this: Recognize it as a high-risk, speculative biotech, not a guaranteed multi-bagger. Keep position size small and track FDA, 8-K, and trial data closely. Want to follow up with institutional SEC filings or public grant records for PSTV? I can show you exactly where.

Zestyclose-Storm-270

If you want proof. Do your DD.. Not ALL penny stocks are pump and dumps. Starting next month, PSTV is rolling out its CNSide diagnostic platform in Texas at major cancer centers like MD Anderson and UT Southwestern . This isn’t a theory or fabricated reddit chatter . I did some really good DD on this one ...it’s real. Commercial action starting in the beginning August I mean.. don't you wish you got in on MRNA (MODERNA) before COVID?? It went from .70 to over $450!!! Imagine the early days of a biotech stock going from $0.50 to $3… or even $10+. PSTV is just DAYS away from liftoff.

Zestyclose-Storm-270

They JUST dropped CNSide, a brain cancer test so advanced it can detect deadly tumors with just fluid from your spine WITH NO SURGERY! It’s now rolling out across huge cancer hospitals in Texas like MD Anderson and Baylor. This thing is real, in the market, and ready to bring in serious money. The government is basically handing them bags — $17.6 million in Grants instead of dumping shares like most penny stocks, PSTV is getting paid by the government and medical research orgs.

Immediate-Sky9959

Was a Summer Intern during Junior and Senior years in college. Spent my senior year on the Floor at my Firm's Booth. Next to our BOOTH was Paine Webber and Art Cashin. I probably spent more time listening to him than the guys in our Booth. The Men in our Booth were brilliant, But, Mr. Cashen was the next level. I did get an offer right after graduation to be a Junior on the Prop desk, and I took it. Made it a Point at least once every quarter until I retired to have dinner with Mr. Cashin at Bobby Vans . He could talk the hands off a clock but it wasn't BS. You can't learn what he knew from any AI program. I learned feeling the market, understanding buy and sell volume towards close, who and what was BS, the list goes on and on. Traded on the Prop Desk for 10 years until they shut it down, then was a Rates trader for the next 15 yrs. Retired MD of the desk. And the defining moment of my career is when Mr. Cashin came to our Office( we were the enemy) and congratulated me on the promotion. We went to Bobby Vans that night and celebrated all on his DIME. When Webber became UBS we didn't see much of each other, except for the occasional Holiday Drink. Mr.Cashen passed away 2024 and the young age of 83 and was still the GENERAL of THE FLOOR. AMEN and GOd Bless

Minimum-Purchase7401

• July 31, 2025: The company announced a U.S. launch of its CNSide® diagnostic platform scheduled for August, starting with major cancer centers in Texas such as UT Southwestern and MD Anderson

dr_kmc22

Not with that attitude! I'm sure you could find a girl with an MD

creemeeseason

Right? KFS also owns plumbing companies where there's also a shortage of labor. Great stuff. MD another nice play on that shortage. The labor mismatch in the US is an under talked about problem. Trades, nurses, anything blue collar is in desperate need of workers.

Rando1ph

I have a few buddies that are FA's and they joke that "MD" stands for money dumb. so there is that. But I get it, they are very specialized in the medical field.

whattheheckOO

What makes you think the average 45 year old doctor has no debt? Lol, most of them still have 6-figure student loans at that point. Unless you had wealthy parents foot the entire bill or got an MD/PhD, but that's rare. Also, few docs are earning $500k.

Open_Scratch4447

IXHL Hiring a new MD onto their advisory board with P2 readout coming soon sounds like they have confidence in bringing their new drug into the market eventually.

Classic-Finish-7433

All good points as to the drop today. I’m not invested in PGEN, but became aware of the orphan drug they’re developing from the MD tech awards where their CEO won this year. They’ve invested heavily in their manufacturing capabilities. I’m backing another phase 3 respiratory drug in SVRA since my work does testing for them but FDA rejected their BLA submission because they’re trying to manufacture in Argentina

Aggravating-Elk-7409

SUPREME REGARD ALERT This dude is legit regarded or schizophrenic or both. He’s claiming to be a CFA with years of experience and a doctor specializing in MD. Don’t trust what he says but also keep in mind the others responding to this are also regard pumpers investing in penny stocks

thespacecpa

Read their financial statements and the MD&A, understand their competitors and their financials (benchmark against), research the leadership team and board of directors, understand their connections in the industry and the future outlook of the industry. If you dont understand what the company does or cannot articulate it dont invest or chase.

Jaquing-Porneaux

Executive Summary Palisade Bio is advancing PALI-2108, a novel, orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug for the treatment of ulcerative colitis (UC). The company has recently reported positive topline results from its Phase 1a clinical trial and is proceeding with a Phase 1b study. Financially, the company is in a precarious position, with a limited cash runway that will necessitate additional funding in the near future. The management team, however, brings relevant experience in drug development and financial management. The competitive landscape for IBD is crowded, but PALI-2108's targeted delivery mechanism could offer a key differentiator. The success of Palisade Bio hinges on the continued clinical advancement of PALI-2108 and the company's ability to secure the necessary capital to fund its operations. Financial Analysis: A Precarious Path Forward A thorough review of Palisade Bio's SEC filings paints a picture of a company with a critical need for capital. As of the latest quarterly report for the period ending March 31, 2025, the company's financial position is characterized by: * Limited Cash Runway: While specific current cash on hand is not publicly available, analysis of past burn rates and recent financing activities suggests a limited operational runway. The company will need to secure additional funding to advance PALI-2108 through further clinical trials. * Recent Financing: In December 2024, Palisade Bio closed a $5 million underwritten public offering. Such financing activities, while necessary for survival, can lead to shareholder dilution. * Negative Earnings: As a clinical-stage company with no commercial products, Palisade Bio has a history of negative earnings per share (EPS). This is typical for the sector but underscores the long road to potential profitability. Investors should closely monitor the company's cash burn rate and any future financing announcements, as these will be critical determinants of its viability. Clinical Pipeline: PALI-2108 Shows Early Promise Palisade Bio's clinical pipeline is currently centered on a single asset, PALI-2108. * PALI-2108 for Ulcerative Colitis: This oral PDE4 inhibitor is designed as a prodrug, meaning it becomes active only when it reaches the colon. This targeted approach aims to minimize the systemic side effects, such as nausea and vomiting, that have plagued other oral PDE4 inhibitors. * Positive Phase 1a Results: In May 2025, the company announced positive topline results from its Phase 1a single-ascending dose trial of PALI-2108 in healthy volunteers. The drug was reported to be well-tolerated and demonstrated the intended colon-specific activity. * Phase 1b Underway: Following the successful Phase 1a, Palisade Bio has initiated a Phase 1b multiple-ascending dose study in patients with ulcerative colitis. The results from this trial will be a significant catalyst for the company. * Precision Medicine Approach: The company has entered into a collaboration with Strand Life Sciences to leverage bioinformatics and identify biomarkers that could predict patient response to PALI-2108. This precision medicine strategy could enhance the probability of success in later-stage trials. The early clinical data for PALI-2108 is encouraging, but the drug is still in the very early stages of development. The path to regulatory approval is long and fraught with potential setbacks. Management and Corporate Governance: Experienced Leadership at the Helm Palisade Bio is led by a management team with experience in both the scientific and financial aspects of the biopharmaceutical industry. * JD Finley, Chief Executive Officer: Mr. Finley has a background in finance and has been instrumental in securing capital for the company. His financial acumen will be crucial as Palisade Bio navigates its current financial challenges. * Mitchell Jones, MD, PhD, Chief Medical Officer: Dr. Jones brings extensive experience in gastroenterology and clinical development. His expertise will be vital in guiding the clinical strategy for PALI-2108. * Recent Board Addition: In July 2025, the company appointed Emil Chuang, MB BS FRACP, to its Board of Directors. Dr. Chuang has a track record of successful clinical development in IBD, further strengthening the company's expertise in its target therapeutic area. The experience of the management team and board provides a degree of confidence in the company's ability to execute its clinical and financial strategies. Competitive Landscape: A Crowded Field with a Niche Opportunity The market for IBD treatments is a multi-billion dollar industry dominated by large pharmaceutical companies with established biologic therapies. However, there is a significant unmet need for safe and effective oral treatments. * Direct Competitors: The oral PDE4 inhibitor space for IBD includes other companies in various stages of clinical development. A key differentiator for Palisade Bio will be to demonstrate a superior safety and efficacy profile for PALI-2108, leveraging its colon-targeted mechanism. * Broader Competition: Beyond other PDE4 inhibitors, PALI-2108 will compete with a wide array of oral and injectable therapies with different mechanisms of action. Palisade Bio's success will depend on its ability to carve out a niche for PALI-2108 by proving a tangible clinical benefit, particularly in terms of safety, over existing and emerging therapies. Conclusion: High-Risk, High-Reward Proposition Investing in Palisade Bio at its current stage is a speculative endeavor with the potential for significant returns, but also the risk of substantial loss. The company's future is almost entirely dependent on the successful clinical development and eventual commercialization of PALI-2108. Key catalysts for investors to watch include: * Results from the ongoing Phase 1b trial of PALI-2108. * Announcements of any new financing activities. * Updates on the collaboration with Strand Life Sciences and the development of a biomarker strategy. * Initiation of a Phase 2 clinical trial for PALI-2108.

reznor504

A MD client told me the hospital changed their graphics cards to “Invidia” (sp) and it’s a game changer for their imaging centers. I bought 100 shares August 18, 2015. Wish I bought 100,000

MossfonBVI

Dennis Levine, MD at Drexel, says without pause that Meta will continue the slide and pull nvda down with it. Levine, with his network of contacts on the street, has it on good authority that since these two have led most of the rally, it would follow that they will pull the rest of the market down with them. You heard it here first !

DebitSuisseQ

It’s incredibly easily treatable with electrolytes and antiobiotics -MD.

ManBearPig_1983

You’re right. I never expected that half a million was the going rate for an MD license. I’ll be sure to steer clear of Dr. debt. Sounds like he’d take my wallet while I’m under.

Meme_Stock_Degen

What is with the dumbass gate keeping. I’m gonna keep posting and your mom who I’m over billing can lick my balls (unless one of my MD colleagues already overbilled for her death)

Monsterpiece42

Mind your manners. That's a TikTok MD to you.

nostraRi

I’m a high functioning autistic MD 🙌I self diagnosed myself since my mum always says I’m special with a wink

Professional-Gear88

I agree. Theyre much too high functioning. Am MD. Downvotes are from the arm chair psychs that have their degrees from TikTok. It’s obnoxious.

Srnkanator

Having worked with ASD children, grown up with an ASD stepfather, and experiencing my own son who is 10 deal with ADHD and OCD requiring medication and therapy. My MS in Psychology and my wife's MD in pediatrics I cannot tell you if any of them are on the ASD spectrum. But my monwy would actually be on none of them.

lymondfc

If you want info from an MD, doctor of the year, who works with these kids - instead of an occupational therapist - you can read the FDA petition submitted here in May requesting to cancel the adcom: [https://www.regulations.gov/document/FDA-2025-P-1355-0001](https://www.regulations.gov/document/FDA-2025-P-1355-0001)

Gathering_Sky

If all those big TSLA shareholders like CA pensions, MD pensions, union pensions, and fund managers, have to sell 200 billions because TSLA is out of compliance with annual meeting and proxy filing regulatory requirements.....will the Saudis still be willing to jump in and keep the share price above 300?? 👀 TSLA 250p

Immediate-Sky9959

Did you or did you not say "from a technical standpoint overnight lending rates have already begun their usual descent into the toilet both " Having Traded Rates for a MAJOR PRIMARY Dealer for 25 years and my Wife MD of a Major Structure Finance Trading Dept. we both strongly disagree with your Premise. If you really though so you would defend our Thesios , or like most others on Reddit go run and hide in the corner and pout like a little child because someone DARED challenge your Dissertation

Difficult_Eye1412

Insert <House MD pointing finger and grinning.gif>

ThaddeusJP

Much of the tuition dollars go towards (bloated) operational costs, physical plant (people want amazing new facilities) and cost of salaries/benefits for staff and professors (who are only getting older and need more med care). Limited slots for Med/Law/Dental/Etc will also drive up demand. Basically high end schools will charge what the market will bear because they know someone will pay for it. Not for nothing but a JD coming out of Yale will take you much further than some no-name law school, a MD from Johns Hopkins will get you a great job out of residency vs a Caribbean college. Finally some charge what they do simply because they can. Easy to get federal loans are a factor, but a very small one. These changes are going to take anyone who is lower/middle class and lock them out of these chances. Schools will NEVER take prices down in any meaningful amount. The money is already spoken for.

thespacecpa

Read their financial statements and MD&A. Most of these companies burn cash and are not profitable. Also do research on the geopolitical environment and foreign competition. Best of luck with your portfolio allocation and feel free to DM if you have any specific questions on RKLB or LUNR

asimovianxz

Absolutely. The real alpha is in footnotes and MD&A sections that most people skip. We've caught major red flags like accelerating DSO trends, off-balance sheet commitments, and changes in revenue recognition timing that weren't obvious in headlines. Key things to hunt for: working capital deterioration, covenant ratios approaching limits, segment profitability buried in geographic breakdowns, and mgmt discussion tone shifts quarter-over-quarter. The challenge is processing volume efficiently - most 10Ks are 200+ pages of dense text. We use AI to flag anomalies first, then dig deep on the interesting bits. Manual reading everything is unrealistic at scale. Pro tip: compare footnote 1 (accounting policies) year-over-year. Companies telegraph problems through policy changes before they hit the income statement.

bombaytrader

this true. I told me dr I am on subreddit. He be like whats a reddit. Dude is a great MD but come on.

gizamo

Due to the clear validity of this implied warning, I'm going to just assume that Dr Dastardly here has an MD and probably a PHD to back it up.

indigo_dreamer00

Imagine being an MD losing money on WSB

BanksCarlton

Hey fam I’m an actual doctor, US MD. Just a heads up their product AL001 is lithium proline and salicylate… which they are trialing for Alzheimer’s. This will absolutely NOT treat nor cure Alzheimer’s. This will likely prove itself as symptomatic relief of few patients who exhibit labile mood and/or outbursts. My warning: The product itself can easily be bypassed with medications available and as a prescriber I will use their data to justify symptom treatment of the select patients who fit profile. But you I’m sure you can pick up on my redundant undertones. Why would I need to justify to begin with if there are already treatable symptoms. Why would I seek bolstered evidence when i understand the physiology of available “replica” modalities..

rockelscorcho

Dammit I'm a doctor! I graduated from the Wharton School of Business and my MD is from Trump University!

creemeeseason

Anyone research MD (pediatrix)? They used to operate a ton of medical divisions, but have divested everything except their NICU operations. Stock is getting beat down as revenue declined (due to having fewer units) but looks to be stabilizing as they focus on their core business. Also, at hospitals with NICUs there are staffing requirements to keep the NICU open and NICU services are not something you generally skimp out on when you need them.

WingedTorch

Yeah Ecstasy commonly contains MDMA/MDA but may also contain other shit or no MD\*A at all.

ChoiceIcy2056

Several Major RED FLAGS with this company (SLS) Source: I attended medical school in the midwest. 1. CEO has concerning credentials. He does not list the school from which he got his MD, and lists it just as "US medicine." 2. The company's approval from FDA is for "Orphan Drug designations" which is for drugs/treatments that affect less than 200,000 people in the US, and is arguably much easier to obtain than other FDA approvals. It gives tax free clinical trials and a few other benefits, but is entirely distinct from the drug approval, which is the real approval that matters. 3. WT-1 gene is known as a tumor suppressor gene although in certain circumstances it can be oncogenic. In laymen terms, this means WT-1 suppresses or fights cancer but can sometimes make cancer worse in certain situations. Targeting this gene may not help you get rid of cancer for the aforementioned reasons.

MontyNinjaPython

The AI says "Aurora Cannabis Q4 2025: Zacks vs. Seeking Alpha – Conflicting Reports and ErrorsAurora Cannabis (ACB) released its Q4 fiscal 2025 results (ended March 31, 2025), but reports from Zacks and Seeking Alpha don’t align, and Zacks seems to have some errors. Here’s a breakdown for clarity: Aurora’s Official Numbers (from their press release): * Revenue: C$90.5M, up 34% from C$67.4M in Q4 2024. * Net Loss: C$17.2M, improved from C$20.3M loss in Q4 2024. * Adjusted EBITDA: C$16.7M, up 619% from C$2.3M. * Outlook: Expects slightly lower global cannabis revenue in Q1 2026 due to temporary international market declines but positive EBITDA and free cash flow. Zacks Report Issues: * Revenue Error: Zacks says revenue was $63.07M USD, beating estimates by 1.65% ($62.04M). But Aurora reported C$90.5M CAD ($66M USD at 0.73 exchange rate). Even converting, Zacks’ number is too low, possibly excluding plant propagation revenue (C$13.8M) or using wrong data. * Earnings Misleading: Zacks reports $0.07/share earnings, missing $0.11/share estimate (-36.36%). This is likely adjusted EPS, ignoring Aurora’s C$17.2M net loss (\~C$0.32/share loss). Focusing only on adjusted EPS hides the actual loss. * Year-Ago Comparison: Zacks says Q4 2024 revenue was $49.98M, but Aurora reported C$67.4M. This mismatch suggests Zacks might be using USD or excluding segments without explaining. Seeking Alpha Report: * Accurate Numbers: Reports C$90.5M revenue, matching Aurora’s press release, with a beat vs. Bloomberg’s C$88.8M estimate. Net loss of C$17.2M and Q1 2026 outlook also align. * Market Reaction: Notes a \~17% premarket stock drop due to concerns about weaker international revenue in Q1 2026, which matches Aurora’s guidance. What’s the Deal? * Zacks’ Errors: Wrong revenue ($63.07M vs. C$90.5M), unclear currency (USD vs. CAD), and focusing on adjusted EPS while ignoring the net loss misleads readers. Their year-ago revenue ($49.98M) doesn’t match Aurora’s C$67.4M either. * Seeking Alpha: More accurate, sticks to Aurora’s official numbers, and highlights market concerns about the Q1 2026 outlook. * Why the Conflict?: Zacks likely uses USD and adjusted metrics (common for analysts) but doesn’t clarify, and their revenue seems off. Seeking Alpha uses CAD and Aurora’s full numbers, making it more reliable. Takeaway: Trust Aurora’s press release (C$90.5M revenue, C$17.2M loss) over Zacks’ report, which has errors. Seeking Alpha’s take is closer to the truth but check Aurora’s MD&A on their website (www.auroramj.com) (www.auroramj.com) for full details."

Flolife2

Damn MD sucks theres really a contributory negligence claim?! Wtf man i got rear ended yea i might have “break checked” but wtf man she shoulda never hit me

greentreesonlyplease

I can't help with creating or mimicking official documents like drug test results — even for demonstration purposes — because it can be misused or misinterpreted. This includes using real company logos or mimicking legitimate forms, which crosses ethical and legal boundaries. However, if you’re looking to design a fictional or stylized "lab report" for a creative project, I can help you make something that looks inspired by medical paperwork — without copying any real companies or being easily mistaken for a genuine document. Let me know if you'd like a version like that (clearly marked fictional), and what you'd use it for — e.g., a story, film prop, etc. I can't help with creating or mimicking official documents like drug test results — even for demonstration purposes — because it can be misused or misinterpreted. This includes using real company logos or mimicking legitimate forms, which crosses ethical and legal boundaries. However, if you’re looking to design a fictional or stylized "lab report" for a creative project, I can help you make something that looks inspired by medical paperwork — without copying any real companies or being easily mistaken for a genuine document. Let me know if you'd like a version like that (clearly marked fictional), and what you'd use it for — e.g., a story, film prop, etc. [NORTHWEST TOXICOLOGY SERVICES] Independent Laboratory & Screening Solutions 1234 Meridian Way, Portland, OR 97201 | (800) 555-7213 | www.nwtoxilab.com --- URINE DRUG SCREENING REPORT Client Name: Jaxon R. McBride DOB: 03/14/1991 Sample ID: NTS-0243817 Collection Date: 06/12/2025 Test Date: 06/13/2025 Report Date: 06/14/2025 Test Type: 12-Panel Urine Toxicology Screen Specimen Integrity: Valid, Temp: 94°F --- TEST RESULTS Drug / Metabolite Result Cutoff Level Interpretation Amphetamines Negative 1000 ng/mL Below Threshold Cocaine Metabolites Negative 300 ng/mL Below Threshold Opiates (Codeine, Morphine) Negative 2000 ng/mL Below Threshold Methamphetamine Negative 500 ng/mL Below Threshold Marijuana (THC-COOH) Positive 50 ng/mL Detected Phencyclidine (PCP) Negative 25 ng/mL Below Threshold Benzodiazepines Negative 300 ng/mL Below Threshold Barbiturates Negative 300 ng/mL Below Threshold Methadone Negative 300 ng/mL Below Threshold MDMA (Ecstasy) Negative 500 ng/mL Below Threshold Synthetic Cannabinoids (K2/Spice) Negative 20 ng/mL Below Threshold Oxycodone / Oxymorphone Negative 100 ng/mL Below Threshold --- Medical Review Officer (MRO): Dr. Sandra R. Malik, MD, MROCC Certified Signature: [Digitally Signed] Date Verified: 06/14/2025 --- NOTE: This report is for informational and demonstrative purposes only. Not valid for legal or clinical use. --- Would you like this turned into a styled PDF or image for visual presentation?

GoZukkYourself

Piper Sandler today raised its price target on $MD to $140 up from $125 while maintaining its Overweight rating

Faxon

I still can't believe that after running MD into the ground the way they did, due to safety fears and crashes and mismanagement, that when Boeing bought them out, they agreed to let ANY of them become managers at Boeing, a company with an impeccable safety record up to that time by comparison. Instead they let the rot seep in and infect them too, and this is the result. It's almost as if not every industry should be run on the razors edge of safety for maximum profit, and we already learned this lesson about air travel the hard way.

bipolarxpres

|Shahed 136| |:-| |Warhead weight|50 kilograms (110 lb)| |Engine|MD-550 piston engine| |Operational range|**2,500 km (1,600 mi)**|

EnginrA

Move to MD

iThinkiStartedATrend

I got offered a job that’s on the other side of the country. It’s everything I want to do, but I don’t want to live in MD. What should I do?

apollo701

Calls it is. I live in MD and one of my good friends works there. This company is far from a scam

Classic-Finish-7433

Why would I? I’m not talking about the SPAC guy like OP. My original comment was referring to the former CEO/ current pres, that was named Tech CEO of year in MD. Still owns over 261M shares of IonQ and only selling 0.00644% of his shares..

CommonSensePDX

I'm not trying to be a complete dick, but come on man. Instead of argument with me, do some basic research because this isn't complex: 1. Much of the reduction in Federal staff was prior to May. Even still, the recent numbers show a continued reduction in Federal employees. 2. State hiring if offsetting that. In fact, states are specifically targeting the DOGE fires. States like MD, VA, PA, NY are relaxing hiring rules and equating federal experience to state civil service requirements. 3. Demographic trends continues to drive healthcare hiring, I hope I don't need to explain this further. Many of these federal employees have valuable skillsets to state and local, e.g. procurement, finance, and IT. They're not fudging the numbers anymore than anyone else. Private sector hiring is not robust, and the numbers are quite clearly indicating as much.

PristineDiscount3208


One-Yard9754

I didn’t chat gpt that you asshole, it’s straight from the quarterly reports! I’m not going into the effort to find the deferred taxes check the MD&A if you want to find the exact amount - I told you the LTD.

Immediate-Sky9959

A- Wife is an MD in an Investment Bank running a Structured finance Team. I'm sure you are vastly familiar with that. B- After a night of drinking coffee and eating cannoli, she had Tea and Napoleans. she wanted me to tell you if you were so great you could make a fortune at a real well financed Firm. Her Firm will hire you in a minute and if you are who you say you are 10yrs and you can retire. We decided against drinks and went for desserts. Prepare for NFP and makes lots of money today on the crumbs, GOMER

R009k

Read Brain Energy by Chris Palmer MD and laugh at our mental health institutions/treatments with me.

Electrical_Ad_828

I, too, have learnt an expensive lesson on BMGL. Wiped out my gains from KDLY MD. And bad luck on my other stocks (looking at you INAB; plz show me green)

four_twenty_4_20

The reason it's happening to AYRA and not Curaleaf or verano is right in the NR title...more info is in the body of the NR too... AYR Announces Delay of Q1 2025 Financial Statements and MD&A, Expected Cease Trade Order and Strategic Review Process

Rare-ish_Bird

Kentucky federal case petition to eliminate minority quotas in all gov't contracting, if successful, will upend the industry. Looking at poots on Booz and Accenture, and the MD economy.

ArthurDent4200

Graduate med school, or complete internship? Once income from employment from MD, the bills will go away quickly if you prioritize their repayment. Until then, I would pay minimum and look forward to the day the income shoots up. After I graduated, I opened up my private practice. Paid minimums, found after a short while, I had cash to knock off my higher interest loan. Cut the check. Money accumulated and knocked off the next one. THAT day was the day I owned my own education. Less than 2 years after I started my practice. Loan 5 is a small amount. You should be able to knock that one off easily! Good luck on your future. You will need shades. Art

MorganC39

I haven't seen anyone talking about the Kindly MD (NAKA) surge on here... up over 1000% in the last 3 weeks!

AcanthisittaBest3033

I keep it simple and repeatable. Start with a screener - something like Finviz, or TakeProfit.com stock screener - to filter by sector, valuation, and volume. I'm usually looking for **strong FCF**, **stable margins**, and **insider ownership**. Quick “no” comes from red flags: \- declining revenue with rising debt, \- excessive dilution, \- or inconsistent accounting. If it passes the screen, I’ll skim the 10-K (especially MD&A and risk section), earnings transcripts, and check how the company actually makes money. I avoid hype and focus on business quality + capital allocation. If I can’t explain how they make money in two sentences, I move on.

NxNW10

Exton and Granowitz, MD have made it clear they are looking to partner. Artal knows LXRX cannot launch in HCM or pain as evidenced by the sota launch failure. Is it a partnership or acquisition and I thought Pfizer best suited over AZ or Lilly. However, Vertex needs LX9211 for chronic pain. VX-548 is not the answer … no fast track from the fda like lx9211.

wsb_moonshot

Yes, MD observed.

jefbe80

Possible play for tomorrow already up 35% from close Anchorage Digital to become the exclusive custodian and trading partner SALT LAKE CITY, UT / ACCESS Newswire / May 21, 2025 / Nakamoto Holdings Inc. ("Nakamoto"), Kindly MD, Inc. (NASDAQ:KDLY) ("KindlyMD"), and Anchorage Digital today announced a strategic partnership to advance the future of corporate Bitcoin adoption. Through this partnership, Anchorage Digital, home to the only U.S. federally chartered digital asset bank, will provide exclusive custody and trading services to KindlyMD for its Bitcoin treasury operations once the merger with Nakamoto closes. Nakamoto, a holding company founded by Bitcoin visionary David Bailey, and KindlyMD aim to establish a Bitcoin treasury strategy with their recently announced merger agreement. The parties secured approximately $710 million in financing, including approximately $510 million in a PIPE, marking the largest PIPE for any public crypto-related transaction. "In the not-so-distant-future, the omission of Bitcoin on a balance sheet will be more glaring than its inclusion. Until then, companies like Nakamoto-KindlyMD are pioneering a new path forward-one in which Bitcoin is at the heart of corporate strategy."

MikeHoncho1323

If your company is convicted of defrauding either organization they can strip your ability to collect both, just look up the law. I’m not grasping at anything I’m just stating facts. Back in nursing school I had a professor (NP)who was convicted of Medicare fraud with her MD husband and they were barred from both and had to pay massive penalties. Obviously a large company isn’t treated the same as a mom/pop home health company but the potential is still there for them to get absolutely shafted. That being said I bought more shares today, but it’s not a company I’d put a majority of my portfolio in.

BooBrew32

Dr. Donald Trump Jr. MD using his galaxy brain here.

EdmundCastle

You can’t target NOVA, unfortunately. Have you looked in MD or WV? You may have more luck there with your numbers.

LowCalligrapher2455

Many Ivy League graduates started private equity, hedge funds and VC’s back in the day and they had a bias of hiring employees from those same schools so it became a self-fulfilling process. The private equity firm I worked at had the same bias but by the time I retired, they were promoting the very best junior staff to MD levels without the need for an Ivy League MBA.

Mobile-Market-6397

MD

badman_dont_PM_me

Every single thing they sell is a pointlessly compounded drug, soon to be banned GLP-1’s aside. They aren’t offering special sauce just charging 10x the price to put two dirt cheap generics in the same pill. 90% of what they offer is mundane medicine that any NP, MD or urgent care clinic write a script for if you just ask and insurance would cover that. The other 10% is weakly evidenced and more than likely a waste of money. It takes 10 minutes of looking at your insurance plan telehealth options to make Hims totally obsolete.

naked_space_chimp

Right, that's what you'd think but he isn't. He is a doctor, more like A MD. 

awetfartruinedmylife

Lmfao the Advanced MD

IsNullOrEmptyTrue

Probably just a somatoform reaction, or else just a muscle twitch. You'll be fine Sincerely, Not an MD or a Therapist

CannaVestments

Relatively stable Q1 showing from Terrascend- results were near consensus with top-line just short but a better margin profile than expected, a good result in the face of ongoing price compression in most markets. Growth prospects for the year are seemingly tied to incremental M&A (1 new store closed in OH w/ 1 more store deal announced in NJ), as well as smaller CapEx projects (a 50% canopy expansion in MD recently completed and NJ manufacturing expansion), needed given increased retail competition/price compression that has driven the top-line down 12% YoY. Current cash flow generation is still reliant on 280e deferrals, with tax-adjusted OCF just above breakeven in Q1. A fairly clean balance sheet (minimal near-term debt owed, low leverage on real estate) puts the company in a better position than most Tier 2 peers. Full review: **Revenue:**  QoQ: $74.4 to $71.0M / YoY: $80.6M to $71.0M *Down 4.6% sequentially and 11.9% YoY, just slightly short of expectations ($72M) with management highlighting seasonal declines. No new assets online in Q1 but Terrascend has since announced the closing of 1 new store in OH and an agreement to purchase a store in NJ in Q2. Retail revenue was down 6.4% QoQ (mostly MI and NJ) while wholesale was flat.* **Adjusted EBITDA:**  QoQ: $15.1M to $15.3M / YoY: $16.2M to $15.3M *Up slightly QoQ and down slightly YoY, ahead of expectations ($14M). Margin expanded from 20.1% last year and 20.3% in Q4 to 21.6% here in Q1- a solid result in the face of ongoing price compression in most markets as OpEx reductions combined with better gross margins.* **Gross Margins:**  QoQ: 50.2% to 51.8% / YoY: 48.0% to 51.8% *Nice result here- management highlighted improved margins in Maryland in particular and steady performance in NJ.* **Operating Expenses:**  QoQ: $28.9M to $28.1M / YoY: $32.7M to $28.1M *Solid OpEx reduction QoQ and YoY, especially in light of store openings during that time.* **Operational Cash Flow:**  QoQ: $9.7M to $8.0M / YoY: $13.3M to $8.0M *Down slightly QoQ and YoY but have to look at tax dynamics. Tax-adjusted OCF was slightly positive in Q1 at +$0.3M, down from +$4.4M last year. CapEx spend was $2.5M so FCF was +$5.5M on a reported basis and -$2.2M on a tax-adjusted basis, much better than most Tier 2 peers.* **Cash:**  QoQ: $27.0M to $29.2M / YoY: $26.4M to $29.2M *Rise here as positive OCF offset CapEx spend. Debt stands at $190.4M, income tax payable at $11.5M, and an uncertain tax position of $114.7M*

Crq_panda

I flew on one last year out of PVG. The interior fit and finish are quite similar to what you'd find on an Airbus. From a functional standpoint—speaking as someone in the aviation industry—it’s comparable to the 737 MAX or A321neo. However, there are two main challenges: Operational Conservatism: Believe it or not, Chinese aviation companies tend to be quite conservative. They operate with a lower tolerance for mechanical anomalies, which results in lower daily aircraft utilization compared to Western carriers operating the same aircraft types. This isn’t necessarily a flaw—just a different operational philosophy. Component Variability and Experience Gap: Even with internationally sourced components, no two aircraft behave exactly the same—this is true even for mature platforms like the 767ER or 757-200, where aircraft just one serial number apart can feel different. In Western fleets, decades of operational experience and engineering support help crews quickly diagnose and manage these quirks. With newer aircraft like the C919, every anomaly—no matter how minor—triggers inspections, simply because the operational history and trust aren’t there yet. COMAC is a capable manufacturer. Some of its factories were involved in producing the MD-80/90 under license, and those aircraft were well-built. The real challenge now is proving that competence to regulators, airlines, and passengers. Chinese airlines, like any airline, are risk-averse by nature. The C919 is still an unknown quantity. The C909, for example, had some noticeable cost-cutting measures. One detail that stood out to me: each row only has three oxygen masks per side, compared to four on Airbus and Boeing aircraft to accommodate lap infants. It’s not a mission-critical issue, but it’s like a loose thread on a $1,000 suit—small, but it affects perception.

Turnup_MD

MD with MA in healthcare administration here. This is actually good. There's no free market on regards to newly designed drugs because they have a patent. Patent can last 10+ years for biologic drugs, which means no competition. I'm unsure of the legality about an EO doing this, but I do know that other healthcare systems have government agencies in place that regulate the price of drugs. For example, the UK has the NICE (National Institute for Health and Care Excellence). This institution regulates the prices of new drugs in the market with some tools like ICER (Incrememental cost-effectiveness ratio). If the pharmaceutical companies do not agree with the price, they get 0 revenue. They always agree because it is better to make some money than nothing at all. I'm not pro Democrat or Republican. I'm just pro not being stupid. I think Trump made a lot of stupid decisions with tariffs? Yeah. One of the 10 basic principles of economics is that trade makes everyone better, and tariffs hurt everyone, some more than others (I expect someone with a bachelor's in economics to know this). Is he going to be able to pull this? I don't know, hopefully. Is there a hidden motive for this change? I hope not. Will pharmaceuticals raise prices in other countries to make it fair, and then Americans are paying the same price? They wish. The strong governments with centralized health system who negotiates drug pricess will tell them to fuck off.

Narezza

I'm a pharmacist in a hospital and I see comments about drug costs in the facility and they often read like this. But your itemized bill isn't just showing you the cost of the med, it also includes everything it takes to get that med. MD writing orders, Pharmacists checking orders, pharm techs resupplying, RN time to find, pull, admin, chart. Not that it makes the price any more palatable, or that there isn't a lot of inflated costs. But its not just the cost of the med.